NO20051847L - Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi. - Google Patents

Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.

Info

Publication number: NO20051847L
Authority: NO; Norway
Prior art keywords: neurosis; bulimia; anorexia; epa; treatment
Prior art date: 2002-09-16

Application number

NO20051847A

Other languages

English (en)

Norwegian (no)

Inventor

David Frederick Horrobin

Agnes Ayton

Original Assignee

Laxdale Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-16

Filing date

2005-04-15

Publication date

2005-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051847(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-15 Application filed by Laxdale Ltd filed Critical Laxdale Ltd

2005-04-15 Publication of NO20051847L publication Critical patent/NO20051847L/no

Links

JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title abstract 4
229960005135 eicosapentaenoic acid Drugs 0.000 title abstract 4
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title abstract 4
235000020673 eicosapentaenoic acid Nutrition 0.000 title abstract 4
208000032841 Bulimia Diseases 0.000 title abstract 2
206010006550 Bulimia nervosa Diseases 0.000 title abstract 2
206010029333 Neurosis Diseases 0.000 title abstract 2
208000022531 anorexia Diseases 0.000 title abstract 2
206010061428 decreased appetite Diseases 0.000 title abstract 2
208000015238 neurotic disease Diseases 0.000 title abstract 2
208000035850 clinical syndrome Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20051847A 2002-09-16 2005-04-15 Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi. NO20051847L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0221480.7A GB0221480D0 (en)	2002-09-16	2002-09-16	Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en)	2002-09-16	2003-09-16	Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number	Publication Date
NO20051847L true NO20051847L (no)	2005-04-15

Family

ID=9944164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051847A NO20051847L (no)	2002-09-16	2005-04-15	Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.

Country Status (20)

Country	Link
US (1)	US20060135608A1 (2)
EP (1)	EP1556028A1 (2)
JP (1)	JP2006503031A (2)
KR (1)	KR20050042823A (2)
CN (1)	CN1694694A (2)
AU (1)	AU2003269138A1 (2)
BR (1)	BR0317857A (2)
CA (1)	CA2499142A1 (2)
GB (1)	GB0221480D0 (2)
HR (1)	HRP20050245A2 (2)
IS (1)	IS7744A (2)
MX (1)	MXPA05002943A (2)
NO (1)	NO20051847L (2)
NZ (1)	NZ538793A (2)
PL (1)	PL375726A1 (2)
RS (1)	RS20050226A (2)
RU (1)	RU2330653C2 (2)
TW (1)	TW200410682A (2)
WO (1)	WO2004024136A1 (2)
ZA (1)	ZA200502161B (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003048831A (ja)	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005046668A1 (ja) *	2003-11-14	2005-05-26	Mochida Pharmaceutical Co., Ltd.	言語障害予防・治療剤
JP4993852B2 (ja)	2004-09-17	2012-08-08	サントリーホールディングス株式会社	ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja)	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP2098229A4 (en)	2006-12-28	2010-03-10	Suntory Holdings Ltd	NERVE REGENERATION MEDIUM
WO2008098375A1 (en)	2007-02-15	2008-08-21	Centre De Recherche Sur Les Biotechnologies Marines	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en)	2007-02-15	2014-08-26	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
CA2677670C (en)	2007-03-20	2010-08-03	Centre De Recherche Sur Les Biotechnologies Marines	Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN106074486A (zh) *	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
CN103354839A (zh) *	2011-02-11	2013-10-16	纳幕尔杜邦公司	二十碳五烯酸浓缩物
US9447020B2 (en)	2013-10-31	2016-09-20	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) *	2013-11-12	2015-04-10	Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы	Способ лечения хронического запора и функциональной анорексии
WO2019153073A1 (en)	2018-02-07	2019-08-15	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) *	2018-04-16	2021-05-06	Quadrant Biosciences Inc.	Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
CA3054203C (en)	2018-05-03	2021-01-05	Scf Pharma Inc.	Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) *	2018-07-30	2021-01-26	中国科学院心理研究所	一种用于筛选高危进食障碍的检测系统
US12226390B2 (en)	2019-07-21	2025-02-18	Scf Pharma Inc.	Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
AU2021242363A1 (en)	2020-03-27	2022-11-03	Homeostasis Therapeutics, Limited	Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9224809D0 (en) *	1992-11-26	1993-01-13	Scotia Holdings Plc	Schizophrenia
US6077828A (en) *	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
2003
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004024136A1 (en)	2004-03-25
JP2006503031A (ja)	2006-01-26
BR0317857A (pt)	2005-12-06
TW200410682A (en)	2004-07-01
RU2330653C2 (ru)	2008-08-10
KR20050042823A (ko)	2005-05-10
RU2005107416A (ru)	2006-01-20
ZA200502161B (en)	2005-09-15
PL375726A1 (en)	2005-12-12
NZ538793A (en)	2007-05-31
US20060135608A1 (en)	2006-06-22
MXPA05002943A (es)	2005-06-03
IS7744A (is)	2005-03-15
GB0221480D0 (en)	2002-10-23
AU2003269138A1 (en)	2004-04-30
RS20050226A (sr)	2007-09-21
HRP20050245A2 (en)	2005-10-31
CN1694694A (zh)	2005-11-09
CA2499142A1 (en)	2004-03-25
EP1556028A1 (en)	2005-07-27

Legal Events

Date	Code	Title	Description
2010-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20051847L (no)	2005-04-15	Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
NO20061736L (no)	1999-08-20	Krystallform av epotilon B
DK1206474T3 (da)	2004-10-04	Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DE60111570D1 (de)	2005-07-21	Isoindolin-1-on als glukokinaseaktivatoren
MY180762A (en)	2020-12-08	Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
SE0102315D0 (sv)	2001-06-28	Compounds
BRPI0413449A (pt)	2006-10-17	compostos de quinoxalina
SG130189A1 (en)	2007-03-20	Substituted indole-o-glucosides
UA87991C2 (en)	2009-09-10	Substituted indole-o-glucosides
MXPA02007099A (es)	2004-08-23	Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
NO20071378L (no)	2007-03-23	Tiazolo-naftylsyrer.
NO20024240D0 (no)	2002-09-05	Nye arylfruktose-1,6-bisfosfataseinhibitorer
ATE312096T1 (de)	2005-12-15	Neue verbindungen
BR0315644A (pt)	2005-08-30	Piperazinil e diazapanil benzamidas e benzotioamidas
IS7858A (is)	2005-05-23	Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
NO20010860L (no)	2001-04-23	Nye forbindelser
DE60305522D1 (de)	2006-06-29	Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
SE0302304D0 (sv)	2003-08-27	Novel compounds
WO2004024064A8 (en)	2005-07-21	Compositions and methods for the diagnosis and treatment of tumor
ATE417856T1 (de)	2009-01-15	Motilidverbindungen
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60316128D1 (de)	2007-10-18	N-sulfonylurea-apoptosis-förderer
EA200200853A1 (ru)	2003-02-27	Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
MY140194A (en)	2009-11-30	Novel fusidic acid derivatives
CY1105345T1 (el)	2010-03-03	Φαινυλαλκινια